Gold prices edge higher on raised Fed rate cut hopes
Joshua B. Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), recently sold shares of the company’s common stock. The transaction, which took place on March 3, 2025, involved the sale of 4,595 shares at a weighted average price of $3.1663 per share, totaling approximately $14,549. The sale occurred as the stock trades near $3.36, with the company currently valued at $205 million. According to InvestingPro analysis, AMLX appears slightly undervalued based on its Fair Value assessment.
The shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, as noted in a footnote accompanying the filing. This sale was automatic and not at Cohen’s discretion. Following the transaction, Cohen retains ownership of 3,196,652 shares in the company. The stock has seen significant volatility, down 84% over the past year, though showing signs of recovery with a 37% gain over the last six months. For deeper insights into AMLX’s valuation and performance metrics, including exclusive ProTips and comprehensive analysis, check out the full research report on InvestingPro.
In other recent news, Amylyx Pharmaceuticals Inc. has received clearance from the U.S. Food and Drug Administration to resume its Phase 1 trial for the ALS drug AMX0114. This decision allows Amylyx to start patient screening and enrollment in the United States, with plans to initiate the trial in Canada as well. The trial, named LUMINA, will assess the safety and biological activity of AMX0114 in approximately 48 participants. Additionally, Amylyx has entered into a collaboration with Gubra A/S to develop a long-acting GLP-1 receptor antagonist for diabetes treatment. The agreement includes potential milestone payments exceeding $50 million and royalties for Gubra. In analyst coverage, H.C. Wainwright reiterated a Buy rating for Amylyx, highlighting the significance of the Phase 3 trial design for avexitide, known as Lucidity. This trial will focus on post-bariatric hypoglycemia, utilizing similar criteria to previous successful studies. These recent developments underscore Amylyx’s ongoing efforts to expand its research and development initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.